연구동향 분석
박사

Development of novel fenofibric acid-loaded controlled release pellet

김경수 2015년

논문상세정보
    • 저자 김경수
    • 형태사항 삽도 ;: 26 cm: viii, 105 p. :
    • 일반주기 권두 Abstract, 권말 국문요지 수록, 지도교수: 최한곤, 참고문헌: p. 91-101
    • 학위논문사항 2015. 8, 한양대학교 대학원 :, 학위논문(박사)-, 약학과,
    • 발행지 서울
    • 언어 eng
    • 출판년 2015
    • 발행사항 한양대학교 대학원,
    • 주제어 약학
    유사주제 논문( 20)
인용/피인용
' Development of novel fenofibric acid-loaded controlled release pellet' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 약학
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
21 0

0.0%

' Development of novel fenofibric acid-loaded controlled release pellet' 의 참고문헌

  • Zhang, X., Chen, G., Zhang, T., Ma, Z., Wu, B., 2012. Effects of PEGylated lipidnanoparticles on the oral absorption of one BCS II drug: a mechanisticinvestigation. Int. J. Nanomedicine. 9, 5503-5514.
  • Yuen, K., Deshmukh, A., Newton, J., 1993, Development and in-vitro evaluationof a multiparticulate sustained release theophylline formulation, Drug Dev. Ind. Pharm., 19, 855-874.
  • Yousaf, A.M., Kim, D.W., Oh, Y.K., Yong, C.S., Kim, J.O., Choi, H.G., 2015, Int. J. Nanomedicine., 10, 1819?1830.
  • Yadav, D., Survase, S., Kumar, N., 2011. Dual coating of swellable and rupturablepolymers on glipizide loaded MCC pellets for pulsatile delivery: formulationdesign and in vitro evaluation. Int. J. Pharm. 419, 121-130.
  • Wright, A.D., Dodson, P.M., 2011. Medical management of diabetic retinopathy:fenofibrate and ACCORD Eye studies. Eye (Lond) 25, 843-849.
  • Wong, T.Y., Simo, R., Mitchell, P., 2012. Fenofibrate - a potential systemic101treatment for diabetic retinopathy? Am. J. Ophthalmol. 154, 6-12.
  • Wan, L.S., Lai, W., 1991, Factors affecting drug release from drug-coatedgranules prepared by fluidized-bed coating, Int. J. Pharm., 72, 163-174.
  • Vonk, P., Guillaume, C., Ramaker, J., Vromans, H., Kossen, N., 1997, Growthmechanisms of high-shear pelletisation, Int. J. Pharm., 157, 93-102.
  • Vervaet, C., Baert, L., Remon, J.P., 1995, Extrusion-spheronisation A literaturereview, Int. J. Pharm., 116, 131-146.
  • Vertommen, J., Rombaut, P., Kinget, R., 1997, Shape and surface smoothness ofpellets made in a rotary processor, Int. J. Pharm., 146, 21-29.
  • Varum, F.J., Merchant, H.A., Basit, A.W., 2010. Oral modified-releaseformulations in motion: the relationship between gastrointestinal transit anddrug absorption. Int. J. Pharm. 395, 26-36.
  • Vanangamudi, M., Rao, T.C., 1984, Kinetic study of agglomerate growth in coaloilagglomeration process. Fuel, 63, 738-743.
  • Tsimihodimos, V., Miltiadous, G., Daskalopoulou, S.S., Mikhailidis, D.P., Elisaf,M.S., 2005. Fenofibrate: metabolic and pleiotropic effects. Curr. Vasc. Pharmacol. 3, 87-98.
  • Trivedi, N.R., Rajan, M.G., Johnson, J.R., Shukla, A.J., 2007, Pharmaceuticalapproaches to preparing pelletized dosage forms using the extrusionspheronizationprocess, Critical Reviews™ in Therapeutic Drug CarrierSystems 24.
  • Tran. P.H., Tran, T.T., Park, J.B., Min, D.H., Choi, H.G., Han, H.K., Rhee, Y.S.,Lee, B.J., 2011, Investigation of physicochemical factors affecting thestability of a pH-modulated solid dispersion and a tablet during storage, Int. J. Pharm., 414, 48?55.
  • Tran, T.T., Tran, P.H., Lee, B.J., 2009, Dissolution-modulating mechanism ofalkalizers and polymers in a nanoemulsifying solid dispersion containingionizable and poorly water-soluble drug, Eur. J. Pharm. Biopharm., 72, 83?90.
  • Tran, T.T., Tran, P.H., Choi, H.G., Han, H.K., Lee, B.J., 2010, The roles ofacidifiers in solid dispersions and physical mixtures, Int. J. Pharm., 384, 60?66.
  • Tran, T.H., Ramasamy, T., Truong, D.H., Choi, H.G., Yong, C.S., Kim, J.O., 2014,Preparation and characterization of fenofibrate-loaded nanostructured lipidcarriers for oral bioavailability enhancement, AAPS PharmSciTech., 15(6),1509?1515.
  • Thommes, M., Kleinebudde, P., 2006. Use of kappa-carrageenan as alternativepelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler. Eur. J. Pharm. Biopharm. 63, 59-67.
  • Tavakoli, N., Minaiyan, M., Tabbakhian, M., Pendar, Y., Preparation andevaluation of a controlled drug release of repaglinide through matrix pellets:in vitro and in vivo studies. J. Microencapsul. 31, 529-534.
  • Tang, L., Schwartz, J.B., Porter, S.C., Schnaare, R.L., Wigent, R.J., 2000, Drugrelease from film-coated chlorpheniramine maleate nonpareil beads: effect of34water-soluble polymer, coating level, and soluble core material, Pharm. Dev. Technol., 5, 383-390.
  • Steiner, G., 2008. Fenofibrate for cardiovascular disease prevention in metabolicsyndrome and type 2 diabetes mellitus. Am. J. Cardiol. 102, 28L-33L.
  • Steckel, H., Mindermann-Nogly, F., 2004, Production of chitosan pellets byextrusion/spheronization, Eur. J. Pharm. Biopharm., 57, 107-114.
  • Smith, H., Puddington, I., 1960, Spherical agglomeration of barium sulphate,Can .J. Chem., 38, 1911-1916.
  • Simo, R., Hernandez, C., 2012. Prevention and treatment of diabetic retinopathy:evidence from large, randomized trials. The emerging role of fenofibrate. Rev. Recent Clin. Trials 7, 71-80.
  • Schmidt, C., Kleinebndde, P., 1999. Influence of the granulation step on coatingpellets prepared by extrusion/spheronization. Chem. Pharm. Bull. (Tokyo) 47,99405-412.
  • Sawicki, W., Łunio, R., 2005, Compressibility of floating pellets with verapamilhydrochloride coated with dispersion Kollicoat SR 30 D, Eur. J. Pharm. Biopharm., 60, 153-158.
  • Sarkar, S., Wong, T.W., Liew, C.V., 2013. Importance of wet packability ofcomponent particles in pellet formation. AAPS PharmSciTech. 14, 1267-1277.
  • Sanganwar, G.P., Gupta, R.B., 2008, Dissolution-rate enhancement of fenofibrateby adsorption onto silica using supercritical carbon dioxide, Int. J. Pharm.,360, 213?218.
  • Rowe, R., 1985, Spheronization-a novel pill-making process, Pharm. Int., 6, 119-123.
  • Rosenson, R.S., 2008. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev. Cardiovasc. Ther. 6, 1319-1330.
  • Rosenberg, J., Degenhardt, M., Breitenbach, J., Reiland, T., Marsh, K., 2003,Formulation comprising fenofibric acid, a physiologically acceptable salt orderivative thereof, Google Patents.
  • Rashid, H.A., Heinamaki, J., Antikainen, O., Yliruusi, J., 2001, Influence of thecentrifugal granulating process on the properties of layered pellets, Eur. J.Pharm. Biopharm., 51, 227-234.
  • Rashid, H.A., 2001, Centrifugal granulating process for preparing drug-layeredpellets based on microcrystalline cellulose beads, University of Helsinki.
  • Pradhan, R., Lee, D.W., Choi, H.G, Yong, C.S., Kim, J.O., 2013, Fabrication of auniformly sized fenofibrate microemulsion by membrane emulsification, J. Microencapsul ., 30(1), 42?48.
  • Porter, S.C., Bruno, C.H., 1990. Coating of pharmaceutical dosage forms. Pharmaceutical dosage forms: tablets 2, 83-85.
  • Piao, Z.Z., Lee, K.H., Kim, D.J., Lee, H.G., Lee, J., Oh, K.T., Lee, B.J., 2010.Comparison of release-controlling efficiency of polymeric coating materialsusing matrix-type casted films and diffusion-controlled coated tablet. AAPSPharmSciTech. 11, 630-636.
  • Pawar, A.P., Paradkar, A.R., Kadam, S.S., Mahadik, K.R., 2004, Crystallo-coagglomeration:A novel technique to obtain ibuprofen-paracetamolagglomerates, AAPS PharmSciTech., 5, 57-64.
  • Panda, R.R., Tiwary, A.K., 2012. Hot melt granulation: a facile approach formonolithic osmotic release tablets. Drug Dev. Ind. Pharm. 38, 447-461.
  • Noonan, J.E., Jenkins, A.J., Ma, J.X., Keech, A.C., Wang, J.J., Lamoureux, E.L.,2013. An update on the molecular actions of fenofibrate and its clinicaleffects on diabetic retinopathy and other microvascular end points in patientswith diabetes. Diabetes 62, 3968-3975.
  • Nobuo, N., 1966, Method and apparatus for making spherical granules, GooglePatents.
  • Millili, G., Schwartz, J., 1990, The strength of microcrystalline cellulose pellets:the effect of granulating with water/ethanol mixtures, Drug Dev. Ind. Pharm.,16, 1411-1426.
  • Maghsoodi, M., Taghizadeh, O., Martin, G.P., Nokhodchi, A., 2008, Particledesign of naproxen-disintegrant agglomerates for direct compression by acrystallo-co-agglomeration technique, Int. J. Pharm., 351, 45-54.
  • Locatelli, I., Nagelj Kovacic, N., Mrhar, A., Bogataj, M., 2010. Gastric emptyingof non-disintegrating solid drug delivery systems in fasted state: relevance todrug dissolution. Expert Opin. Drug Deliv. 7, 967-976.
  • Liu, A., Patterson, A.D., Yang, Z., Zhang, X., Liu, W., Qiu, F., Sun, H., Krausz,K.W., Idle, J.R., Gonzalez, F.J., Dai, R., 2009. Fenofibrate metabolism in thecynomolgus monkey using ultraperformance liquid chromatography97quadrupole time-of-flight mass spectrometry-based metabolomics. DrugMetab. Dispos. 37, 1157-1163.
  • Ling, H., Luoma, J.T., Hilleman, D., 2013. A review of currently availablefenofibrate and fenofibric acid formulations. Cardiol. Res. 4, 47-55.
  • Lin, Z., Zhou, L., Mahajan, A., Song, S., Wang, T., Ge, Z., Ellison, D., 2006, Realtimeendpoint monitoring and determination for a pharmaceutical saltformation process with in-line FT-IR spectroscopy, J. Pharm. Biomed. Anal.,41, 99?104.
  • Lim HT, Balakrishnan P, Oh DH, Joe KH, Kim YR, Hwang DH, Lee YB,Yong CS, Choi HG, 2010. Development of novel sibutramine baseloadedsolid dispersion with gelatin and HPMC: physicochemicalcharacterization and pharmacokinetics in beagle dogs. Int. J. Pharm. 397, 225-230.
  • Lavanya, K., Senthil, V., Rathi, V., 2011. Pelletization technology: a quick review. Int. J. Pharm. Sci Res 2, 1337-1355.
  • Krueger, C., Thommes, M., 2013. Multiple batch manufacturing of theophyllinepellets using the wet-extrusion/spheronization process with κ-carrageenan as96pelletisation aid. Pharm. Dev. Technol. 18, 225-235.
  • Koo, O.M.Y., Heng, P.W.S., 2001, The influence of microcrystalline cellulosegrade on shape and shape distributions of pellets produced by extrusionspheronization,Chem. Pharm. Bull., 49, 1383-1387.
  • Koester, M., Willemsen, E., Krueger C., Thommes, M., 2012. Systematicevaluations regarding interparticular mass transfer in spheronization. Int. J.Pharm. 431, 84-89.
  • Koester, M., Thommes, M., 2010. New insights into the pelletization mechanismby extrusion/spheronization. AAPS PharmSciTech. 11 (4), 1549-1551.
  • Kleinebudde, P., 1995. Use of a power?consumption?controlled extruder in thedevelopment of pellet formulations. J. Pharm. Sci. 84, 1259-1264.
  • Kim, G.G., Poudel, B.K., Marasini, N., Lee, D.W., Hiep, T.T., Yang, K.Y., Kim,J.O., Yong, C.S., Choi, H.G., 2013, Enhancement of oral bioavailability offenofibrate by solid self-microemulsifying drug delivery systems, Drug Dev. Ind. Pharm., 39(9), 1431?1438.
  • Khadra, I., Zhou, Z., Dunn, C., Wilson, C.G., Halbert, G., 2015. Statisticalinvestigation of simulated intestinal fluid composition on the equilibriumsolubility of biopharmaceutics classification system class II drugs. Eur JPharm Sci. 67, 65-75.
  • Keating, G.M., Croom, K.F., 2007. Fenofibrate: a review of its use in primarydyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs67, 121-153.
  • Kawashima, Y., Okumura, M., Takenaka, H., Kojima, A., 1984, Direct preparation32of spherically agglomerated salicylic acid crystals during crystallization, J. Pharm. Sci., 73, 1535-1538.
  • Kandukuri, J.M., Allenki, V., Eaga, C.M., Keshetty, V., Jannu, K.K., 2009,Pelletization techniques for oral drug delivery, Int. J. Pharm. Sci. & Drug Res.,1, 63-70.
  • Kallai, N., Luhn, O., Dredan, J., Kovacs, K., Lengyel, M., Antal, I., 2010,Evaluation of drug release from coated pellets based on isomalt, sugar, andmicrocrystalline cellulose inert cores, AAPS PharmSciTech., 11, 383-391.
  • Jadhav, N.R., Pawar, A.P., Paradkar, A.R., 2011, Preparation and evaluation of talcagglomerates obtained by wet spherical agglomeration as a substrate forcoating, Pharm Dev Technol., 16, 152-161.
  • Huyghebaert, N., Snoeck, V., Vermeire, A., Cox, E., Goddeeris, B., Remon, J.P.,2005, Development of an enteric-coated pellet formulation of F4 fimbriae fororal vaccination of suckling piglets against enterotoxigenic Escherichia coliinfections, Eur J Pharm Biopharm., 59, 273-281.
  • Hellen, L., Yliruusi, J., 1993, Process variables of instant granulator andspheroniser: III. Shape and shape distributions of pellets, Int. J. Pharm., 96,217-223.
  • Hasznos, L., Langer, I., Gyarmathy, M., 1992, Some factors influencing pelletcharacteristics made by an Extrusion/Spheronisation process Part I.: Effectson size characteristics and moisture content decrease of pellets, Drug Dev. Ind. Pharm., 18, 409-437.
  • Harrison, P., Newton, J., Rowe, R., 1987, The application of capillary rheometryto the extrusion of wet powder masses, Int. J. Pharm., 35, 235-242.
  • Harrison, P., Newton, J., Rowe, R., 1985, The characterization of wet powdermasses suitable for extrusion/spheronization, J. Pharm. Pharmacol., 37, 686-691.
  • Hanafy, A., Spahn-Langguth, H., Vergnault, G., Grenier, P., Grozdanis, M.T.,Lenhardt T., Langguth P., 2007. Pharmacokinetic evaluation of oralfenofibrate nanosuspensions and SLN in comparison to conventionalsuspensions of micronized drug. Adv. Drug Deliv. Rev. 59, 419-426.
  • Hamedelniel, E.I., Bajdik, J., Kasa, P. Jr., Pintye-Hodi, K., 2012. Study of theinfluence of alkalizing components on matrix pellets prepared byextrusion/spheronization. Pharm. Dev. Technol. 17, 204-211.
  • Goskonda, S.R., Hileman, G.A., Upadrashta, S.M., 1994, Controlled releasepellets by extrusion-spheronization, Int. J. Pharm., 111, 89-97.
  • Ghebre-Selassie, I., 1989, Pharmaceutical pelletization technology, Informa.Health Care.
  • Garekani, H.A., Nokhodchi, A., Rayeni, M.A., Sadeghi, F., 2013. Preparation andcharacterization and release properties of Eudragit RS based ibuprofenpellets prepared by extrusion spheronization: effect of binder type andconcentration. Drug Dev. Ind. Pharm. 39, 1238-1246.
  • Gandhi, R., Kaul, C.L., Panchagnula, R., 1999, Extrusion and spheronization inthe development of oral controlled-release dosage forms, Pharm. Sci. Technolo. Today, 2, 160-170.
  • Gamlen, M., 1985, Pellet manufacture for controlled release, ManufacturingChemist, 56, 55.
  • Freed, A.L., Silbering, S.B., Kolodsick, K.J., Rossi, D.T., Mahjour, M., Kingsmill,C.A., 2005. The development and stability assessment of extemporaneouspediatric formulations of Accupril. Int. J. Pharm. 304, 135-144.
  • Flament, M., Dupont, G., Leterme, P., Farah, N., Gayot, A., 2004, Development of400 μm Pellets by Extrusion?Spheronization Application with Gelucire 50/02to Produce a “Sprinkle” Form, Drug Dev. Ind. Pharm., 30, 43-51.
  • Filippatos, T.D., Elisaf, M.S., 2011. Fenofibrate plus simvastatin (fixed-dosecombination) for the treatment of dyslipidaemia. Expert Opin. Pharmacother. 12, 1945-1958.
  • Fielden, K., Newton, J., Rowe, R., 1992, The influence of lactose particle size onspheronization of extrudate processed by a ram extruder, Int. J. Pharm., 81,205-224.
  • Fekete, R., Zelko, R., Marton, S., Racz, I., 1998, Effect of the formulationparameters on the characteristics of pellets, Drug Dev. Ind. Pharm., 24, 1073-1076.
  • Duki?-Ott, A., Thommes, M., Remon, J.P., Kleinebudde, P., Vervaet, C., 2009,Production of pellets via extrusion?spheronisation without the incorporationof microcrystalline cellulose: a critical review, Eur. J. Pharm. Biopharm., 71,38-46.
  • Dechesne, J.P., Delattre, L., 1987. A new enteric tablet of acetylsalicylic acid. II. Biopharmaceutical aspects. Int. J. Pharm. 34, 259-262.
  • Davidson, M., Rosenson, R.S., Maki, K.C., Nicholls, S.J., Ballantyne, C.M., Setze,C., Carlson, D.M., Stolzenbach, J., 2012. Study design, rationale, andbaseline characteristics: evaluation of fenofibric acid on carotid intima-mediathickness in patients with type IIb dyslipidemia with residual risk in additionto atorvastatin therapy (FIRST) trial. Cardiovasc. Drugs Ther. 26, 349-358.
  • Conine, J., Hadley, H., 1970, Preparation of small solid pharmaceutical spheres,Drug Cosmet, Ind., 106, 38-44.
  • Clarke, G., Newton, J., Short, M., 1995. Comparative gastrointestinal transit ofpellet systems of varying density. Int. J. Pharm. 114, 1-11.
  • Chopra, R., Podczeck, F., Newton, J.M., Alderborn, G., 2002, The influence ofpellet shape and film coating on the filling of pellets into hard shell capsules,Eur. J. Pharm. Biopharm., 53, 327-333.
  • Cho, K.H., Choi, H.G., 2013. Development of novel bepotastine salicylate saltbioequivalent to the commercial bepotastine besilate in beagle dogs. Drug93Dev. Ind. Pharm. 39, 901-908.
  • Cho KH, Choi YK, Kang JH, Choi HG, Yong CS, Park YJ, 2010.Development of a novel combination tablet containing trimebutinemaleate and mosapride citrate for the treatment of functional dyspepsia.Int. J. Pharm. 400, 145-152.
  • Chanda, D., Lee, C.H., Kim, Y.H., Noh, J.R., Kim, D.K., Park, J.H., Hwang, J.H.,Lee, M.R., Jeong, K.H., Lee, I.K., Kweon, G.R., Shong, M., Oh G.T., Chiang,J.Y., Choi, H.S., 2009. Fenofibrate differentially regulates plasminogenactivator inhibitor-1 gene expression via adenosine monophosphate-activatedprotein kinase-dependent induction of orphan nuclear receptor smallheterodimer partner. Hepatology. 50, 880-892.
  • Chachad, S.S., Gole, M., Malhotra, G., Naidu, R., 2014. Comparison ofpharmacokinetics of two fenofibrate tablet formulations in healthy humansubjects. Clin. Ther. 36, 967-973.
  • Brown, W.V., 1989. Treatment of hypercholesterolaemia with fenofibrate: areview. Curr. Med. Res. Opin. 11, 321-330.
  • Bornhoft, M., Thommes, M., Kleinebudde, P., 2005. Preliminary assessment ofcarrageenan as excipient for extrusion/spheronisation. Eur. J. Pharm. Biopharm. 59, 127-131.
  • Bolcskei, E., Regdon, G. Jr., Sovany, T., Ghanam, D., Knop, K., Kleinebudde, P.,Pintye-Hodi, K., 2014. Preparing of pellets by extrusion/spheronization usingdifferent types of equipment and process conditions. Drug Dev. Ind. Pharm. 9240, 762-764.
  • Bhavesh, D., Shah, S., 2009. Determination of fenofibric acid in human plasma byultra performance liquid chromatography-electrospray ionization massspectrometry: application to a bioequivalence study. Biomed. Chromatogr. 23,922-928.
  • Bhad, M.E., Abdul, S., Jaiswal, S.B., Chandewar, A.V., Jain, J.M., Sakarkar, D.M.,2010, MUPS Tablets?A Brief Review, Int. J. Pharmtech. Res., 2, 847-855.
  • Bataille, B., Ligarski, K., Jacob, N., Thohas, C., Duru, C., 1993, Study of theinfluence of spheronization and drying conditions on the physico-mechanicalproperties of neutral spheroids containing Avicel PH 101 and lactose, DrugDev. Ind. Pharm., 19, 653-671.
  • Balfour, J.A., McTavish, D., Heel, R.C., 1990. Fenofibrate. A review of itspharmacodynamic and pharmacokinetic properties and therapeutic use indyslipidaemia. Drugs 40, 260-290.
  • Baert, L., Remon, J.P., 1993, Influence of amount of granulation liquid on thedrug release rate from pellets made by extrusion spheronisation, Int. J. Pharm.,95, 135-141.
  • Alagona, Jr. P., 2010. Fenofibric acid: a new fibrate approved for use incombination with statin for the treatment of mixed dyslipidemia. Vasc. Health Risk Manag. 6, 351.
  • Abdul, S., Chandewa,r A.V., Jaiswal, S.B., 2010. A flexible technology formodified-release drugs: multiple-unit pellet system (MUPS). J. Control. Release 147, 2-16.
  • Abbaspour, M., Sadeghi, F., Garekani, H.A., 2005, Preparation andcharacterization of ibuprofen pellets based on Eudragit RS PO and RL PO ortheir combination, Int. J. Pharm., 303, 88-94.